Frailty, Sarcopenia
Conditions
Brief summary
This study will assess whether the use of technology using the Virtual Gate Device (VGD) will prevent or minimize the development of hospital acquired Sarcopenia resulting from Immobilization.
Detailed description
Modern advances in prevention, medical care, and treatments have resulted in an ever-increasing life expectancy and aging of the population. As a result, it is imperative that health care professionals and policy makers develop strategies and new technologies that enable older people to enjoy their advancing years in good health. Sarcopenia, an age-related decrease in muscle mass, is a major factor in functional decline and frailty and leads to poor quality of life and increased health care costs in older age groups. Because sarcopenia is known to be exacerbated at the time of acute hospital admission, the development of new technologies for the prevention and diagnosis of sarcopenia will have important ramifications in promoting healthy aging in both the acute care and ambulatory settings. A pilot interventional self-controlled study will be performed in an internal medicine department (internal medicine ward Het) at the Rambam Health Care Campus in Haifa. Subjects will be evaluated for the risk of sarcopenia by acceptable screening instruments as well as B-mode portable ultrasound. They will then be treated using a stocking-like Virtual Gait Device (VGD) which will be applied to one randomly-assigned lower limb. The VGD is a technology that uses fussy-logic technology to stimulate calf muscles in synchrony with the patient's heartbeat, enabling a virtual gait in patients who have limited mobility. Confidentiality will be achieved by applying a unique identifier to each trial subject in accordance with Good Clinical Practice standards.
Interventions
DEVICEVirtual Gate Device (VGD)
A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations for a maximum of 10 days.
Sponsors
Rambam Health Care Campus
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Eligible subjects will be scored either as low-risk for sarcopenia-related adverse outcomes (\<4) or high risk (≥4) via the SARC-F scoring system, and will be evaluated for sarcopenia of the lower limbs using a B-mode portable ultrasound machine used for standard clinical practice at the Rambam Health Care Campus. A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations as outlined in the investigator brochure. On day 4, ultrasound of the lower limbs will be repeated for all subjects, with repeat imaging every subsequent second day for admissions extending beyond 4 days and a maximum of 10 days after the application of the VGD. The study will include all eligible patients in the internal department (internal medicine ward Het) who agree to participate in the study and provide written informed consent.
Eligibility
Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female patients 75 years of age and older. * Patients admitted with an acute infection (clinically from a respiratory or urinary source). * Expected length of hospitalization of at least 4 days. * Patients who are conscious and cognitively able to provide written informed consent as determined by a score of 0 on the 4AT scale
Exclusion criteria
* Male and female patients under 75 years of age. * Expected length of hospitalization of less than 4 days. * A condition limiting the use of the virtual gate device (VGD) due to factors relating to discomfort or safety, including but not limited to: fracture, amputation, local infection, pain, paralysis of one or both lower limbs, cardiac arrhythmia or cardiac pacemaker. * Patients who are unable to or do not provide informed consent for participation. * A score 1 or more on the 4AT scale.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Muscle mass | Day 4 of admission or last measurement prior to discharge for a maximum of 10 days. | Determined by B-mode ultrasound measurement. |
Countries
Israel
Contacts
Primary ContactTzvi Dwolatzky, MD
Backup ContactElad Rubin
Outcome results
None listed